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Abstract
Prophylactic antibiotics in acute necrotizing
pancreatitis is controversial. The mortality of acute
necrotizing pancreatitis is 8-25% in the western world. In view
of the limited resources available for managing the
complications of infected pancreatitis in developing countries,
the use of prophylactic antibiotics may be recommended in
selected cases.
Various antibiotics show good penetration into the
pancreatic tissue; imipenem and quinolones have better
penetration. Clinical trials on the use of prophylactic
antibiotics in necrotizing pancreatitis have been reviewed.
Prophylactic antibiotics have been considered if
greater than 30% pancreatic necrosis as documented by CT
scan. Imipenem can be given for a duration of 10 to 14 days if
no systemic complications are present. In a developing
country where the cost of managing complications of
pancreatitis can be a limiting factor for patients, the use of
prophylactic antibiotics early on in the disease in selected
cases can be beneficial.
Introduction
The indications for the use of prophylactic antibiotics
in acute necrotizing pancreatitis (ANP) have been
controversial. The use of prophylactic antibiotics should take
into consideration the bacterial spectrum, concentration in
pancreatic tissue, and emerging resistance patterns. In
developing countries, availability and cost of the antibiotic are
important issues, especially when comparing this to the cost of
potential infectious complications in the setting of limited
resources for the care of critically ill patients. Acute
necrotizing pancreatitis has an 8 to 25% mortality reported in
the developed world.1,2A mortality of 20% has been reported
in a non-indexed journal from a center in Lahore, Pakistan.3
This review will attempt to answer certain critical
questions regarding the use of prophylactic antibiotics for
ANP, based on the literature available at this time.
Selection of trials for review:
An advanced search was performed in Pubmed with
the phrase "pancreatitis antibiotics" with 'clinical trials' in
limits. The search returned 74 articles. These were narrowed
down by going through the title and abstracts and ten clinical
trials were identified in which the use of antibiotics were
assessed in acute pancreatitis (Figure-1). 
Impact of prophylactic antibiotics on outcome
in ANP:
Several studies have been conducted to assess the
benefit of prophylactic antibiotics in ANP. Various antibiotics
have been used and have been compared with placebo or each
other. Some of these studies have included patients with
alcoholic pancreatitis only, while others have included patients
with ANP regardless of the cause. 
Pederzoli et al4 recommend the use of prophylactic
antibiotics based on the significantly decreased incidence of
pancreatic sepsis in the antibiotic group of their randomized
trial of 74 patients with CT proven pancreatic necrosis.
Patients were randomized and were either started on
imipenem within 72 hours or no antibiotic treatment. The
incidence of infected pancreatic necrosis (IPN) in the
imipenem group (5 out of 41, 12.2%) was less than half that
of the group without antibiotics (10 out of 33, 30.3%) with a
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Figure 1: Figure showing the selection of clinical trials on antibiotics in acute
necrotizing pancreatitis for review.
p value of less than 0.01. However there was no difference in
mortality between the two groups.
Sanio et al.5 concluded that cefuroxime is beneficial if
given early in ANP as it decreases both infective
complications and mortality significantly. This conclusion was
based on a randomized trial of 60 patients with alcohol
induced ANP. Patients were divided into two groups. One
received cefuroxime for 14 days prophylactically while the
other did not receive any antibiotic unless evidence of
infection was present. Less infectious complications were
observed in the cefuroxime group (p=0.01). Mortality was
also less in the cefuroxime group (1 out of 30, 3.3%) as
compared to the non-antibiotic group (7 out of 30, 23.3%)
with a p value of 0.03. This is the only study showing
significant reduction in mortality with prophylactic
antibiotics. It should be noted that patients included in this
study had alcohol induced pancreatitis.
Delcenserie et al.1 randomized patients with alcoholic
ANP to receive prophylactic ceftazidime, amikacin and
metronidazole for 10 days or no antibiotics. They found a
significant reduction in the incidence of severe sepsis (caused
by culture proven pancreatic infection) in the antibiotic group
(0 out of 11, 0%) as compared to the non antibiotic group (7
out of 12, 58.3%). There was no significant difference in
mortality between the two groups. Røkke et al. showed that
antibiotic prophylaxis with imipenem in patients with severe
pancreatitis (CRP>120 at 24hrs or CRP>200 at 48 hrs)
reduced the complications and incidence of infections.6 There
was no significant difference in length of stay, need for
intensive care, need for surgical intervention or 30 day
mortality.
The clinical course of ANP as assessed by APACHE II
score was compared in a randomized study by Schwarz et al.7
that included 26 patients. They showed significant
improvement in the clinical course of patients receiving
prophylactic ofloxacin and metronidazole (APACHE II scores
at day 1,5 and 10 were 15, 13 and 9.5) as compared to the
control group( scores on day 1,5 and 10 of 11.5, 15, and 16)
that did not receive prophylactic antibiotics. Due to the small
number of patients, differences in mortality could not be
assessed.
The impact of antibiotics on the need for surgical
intervention was evaluated by Nordback et al.4 They
demonstrated a significant reduction in the need for surgery in
patients receiving prophylactic imipenem (2/25, 8%) as
compared to those patients who receive imipenem only when
there is indication of necrosectomy.8
Isenmann et al.9 conducted the first double blind study
of antibiotic prophylaxis in ANP and found no significant
difference in the in the incidence of infected necrosis,
complications or mortality. They compared ciprofloxacin and
metronidazole for 14 days (58 patients) versus placebo (56
patients). However, almost half (48%) of the placebo group
had to be given open antibiotic treatment due to complications
as opposed to 25% of the antibiotic group. The lack of
significant difference in morbidity and mortality might be due
to the fact that most bacteria from the antibiotic group were
resistant to ciprofloxacin. Moreover, infections that developed
in the placebo group were expeditiously treated due to which
a reduction in mortality may not be evident. The authors
suggest that in view of this, administering antibiotics promptly
"on demand" can be effective in preventing infective
complications.
Dellinger et al.2 in a randomized double blind placebo
controlled study found no significant difference between the
outcome of two groups of patients with ANP, one receiving
meropenem and the other placebo. However, there were some
differences between the two groups, although these
differences did not reach statistical significance. The placebo
group had more patients who had greater than 30% necrosis, a
greater proportion of patients with neither alcoholic nor biliary
pancreatitis, and a higher infection rate.
A meta-analysis conducted by Dambrauskas et al10
concluded that prophylactic antibiotics were superior to
administering antibiotics when needed ("on demand") in ANP.
Moreover, they found that carbepenems as prophylactic
antibiotics significantly decreased the risk of developing
pancreatic necrosis, sepsis, and decreased the need for surgery,
although there was no significant change in mortality.
Villatoro et al.11 conducted a Cochrane review of five RCTs
with 294 patients comparing antibiotics to placebo in acute
pancreatitis with CT proven necrosis. They determined a
significant reduction in mortality in the antibiotic group but no
difference in the rates of infected pancreatic necrosis,
operative treatment or non-pancreatic infections. This analysis
was handicapped by the different antibiotics and duration of
treatment in the different trials.
Conversely, a recent meta-analysis by Bai et al.12 of
seven trials involving 467 patients, showed that the incidence
of infected pancreatic necrosis is not reduced by prophylactic
antibiotics and there is no significant decrease in mortality
either. They found that the mortality was significantly
decreased in the antibiotic groups only in single centre trials
and in single blind trials but not in multicentre or double blind
trials. A recent meta-analysis of 502 patients from 8 studies
showed no benefit of antibiotics in decreasing mortality or
morbidity in severe acute pancreatitis.13
In summary, randomized double blind studies have not
shown any significant difference in the outcome with
prophylactic antibiotics. There have been multiple meta-
analyses conducted in an attempt to define the role of
prophylactic antibiotics. Unfortunately, due to the dearth of
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homogenous RCTs, differing inclusion criteria, interventions,
and end-points, the conclusions have been dramatically
varied. The use of prophylactic antibiotics may prove to be
cost-effective in settings where cost and availability of tertiary
care facilities is a significant issue. For instance, 32.6%14 of
the population of Pakistan lives below the poverty line on the
human poverty index.  In such an environment, a strong case
can be made for the administration of prophylactic antibiotics
early in ANP to decrease the incidence of infectious
complications and reduce the cost of patient care.
Bacteriology in ANP: 
The organisms involved in infected ANP vary greatly
and may be influenced by antibiotic usage. In patients with
culture proven infected ANP, microorganisms responsible are
usually of colonic origin15 E. coli and Pseudomonas
aeruginosa were the commonest organisms in acute
pancreatitis in a study in India.16 Howard et al concluded that
prophylactic antibiotics altered the bacteriology of infected
necrosis. They discovered that patients who receive
prophylactic antibiotics for ANP and develop a secondary
infection were predominantly infected by gram positive
organisms. Conversely, gram negative pancreatic infection is
more common in patients who do not receive prophylactic
antibiotics.17
Penetration of antibiotics into pancreatic tissue: 
The concentration of various antibiotics in necrotic
pancreas has been evaluated in humans and experimental
animal models. The penetration of imipenem in the pancreas
in humans is adequate in terms of minimum inhibitory
concentration (MIC) values for common organisms in
infected pancreatic necrosis.18 The concentration of
cefoperazone in pancreatic juice of patients with acute
pancreatitis was higher than the MICs of common pancreatic
pathogens.19 Cefotaxime and ceftizoxime have been found to
have pancreatic tissue concentration for inhibiting some
bacteria involved in pancreatic infections20 while the
concentration of cefoxitin in pancreatic juice was less than the
MICs of commonly involved bacteria. Ciprofloxacin has
higher concentration in both pancreatic juice and tissue than
MICs of common pathogens involved.20 Ofloxacin has good
penetration into pancreatic tissue of rats with induced ANP21
as well as in human pancreatic tissue in ANP. 
Emerging resistance to antibiotics:
Although there are a variety of antibiotics that
penetrate necrotic pancreas, their spectrum of coverage needs
to be assessed. A study by Howard et al.17 demonstrated that
although prophylactic antibiotics change the bacteriology of
infected ANP, there is no significant increase in resistant
organisms. Conversely, the antibiotic group in the Isenmann et
al. trial9 had a significantly higher number of organisms
resistant to ciprofloxacin (p = 0.0001). 
The incidence of resistant organisms in infected
pancreatic necrosis is variable. Infected pancreatic necrosis
due to multi resistant organisms was found in only 3 patients
out of 103 with ANP in a study in Switzerland[22]. Jan et al.15
report 52% (24 out of 46) patients with antibiotic resistant
organisms in an ICU setting. Most common resistant
organisms in this study were Pseudomonas aeruginosa and
methicillin resistant Staphylococcus epidermidis. Out of 11
organisms causing infection in ANP, Dellinger et al. found that
7 were resistant to meropenem (5 out of 6 in meropenem
group and 2 out of 5 in placebo group).2
Choice of antibiotic:
The common bacteria in infected pancreatic necrosis
should have the lowest incidence of resistance to the antibiotic
chosen as prophylaxis in ANP. Although significant mortality
benefit has been shown with cefuroxime as a prophylactic
antibiotic, but imipenem has been used in more trials and is as
effective as meropenem.23 Ciprofloxacin has shown good
penetration but the reported higher incidence of organisms
resistant to it does not make it an attractive choice. The
cephalosporins have not been used as much as the
carbepenems in studies comparing antibiotics. It is important
to review local antibiotic susceptibility data before choosing a
prophylactic antibiotic. Imipenem has shown benefit in
several studies as a prophylactic antibiotic. Based on the
results of trials, meta-analysis, tissue penetration and
bacteriology, it is an effective prophylactic antibiotic in ANP.
Ciprofloxacin is not recommended as first choice because of
high rates of bacterial resistance. Bassi et al.24 conducted a
multicentre study of 60 patients with at least 50% necrosis in
ANP. Patients received either prophylactic imipenem or
perfloxacin. Both antibiotics were given for 14 days. The
incidence of pancreatic infections and sepsis was much less
with prophylactic imipenem as compared to perfloxacin.
Currently, imipenem can be recommended as the
prophylactic antibiotic of choice in ANP although the 27%
resistance reported by Maravi-Poma et al.25 is a cause for
concern. A dosage of 500mg three times a day, as described by
Pederzoli et al4 and Røkke et al6 is recommended.
Duration of antibiotic:
Antibiotics have been used for variable duration in
several studies as shown in Table.  Imipenem was given for 14
days in the majority of studies. In severe pancreatitis Røkke et
al. showed benefit of imipenem even if given for 5 - 7 days.6
Imipenem therapy for more than 14 days in patients without
any systemic complications has not been shown to be superior
to treatment for 14 days with the end point of prevention of
pancreatic infections.25 In addition, in patients with systemic
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complications at day 14 of treatment, prolonging imipenem
administration decreases mortality. No other studies are
available comparing the duration of antibiotic treatment.
As mentioned, the penetration of imipenem into
necrotic pancreatic tissue is best in the initial stages of the
disease. A Cochrane review concluded that antibiotic
treatment for 10 to 14 days decreases mortality and the risk of
developing infected pancreatic necrosis.26 Antibiotics should
be stopped on day 14 if no systemic complications of ANP or
evidence of infection is present as prolonged administration
has not shown any additional benefit. Moreover, prolonged
administration provides favourable conditions for the
selection of resistant organisms. 
Fungal infections:
The incidence of pancreatic fungal infections might be
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Table:  Various clinical trials on prophylactic antibiotics in acute necrotizing pancreatitis with conclusions.
Study Groups Number Infectious Sepsis Need for Mortality Comments Conclusion
of Patients Pancreatic Surgery
Necrosis
Sanio et al6
(1995) --Cefuroxime 14 days 30 9 (30%) 4 (13.3%) 7(23.3%) 1(3.3%)
--No antibiotics 30 12(40%) 8(26.6%) 14(46.6%) 7(23.3%)
Delcenserie
et al.1 (1996) --Ceftazidime+ Amikacin+
Metronidazole for 10 days. 11 0(0%) 0(0%) - 1(9.1%)
--No antibiotics 12 2(25%) 7(58.3%) - 3(25%)
Schwarz et al.7
(1997) --Ofloxacin+ Metronidazole
prophylactically 13 8(62%) 4(31%) - 0(0%)
--Oflaxacin + Metronidazole 
if evidence of infection 13 7(54%) 6(46%) - 2(15%)
Pederzoli
et al.4 (1993) --Imipenum for 14 days 30 5(12.2%) 11(26.8%) 12(29.3%) 3(7.3%)
-- No antibiotics. 30 10(30.3%) 26(78.8%) 11(33.3%) 4(12%)
Manes et al.23
(2003) -- Meropenem for 14 days. 88 10(11.4%) 19(21.6%) 15(17%) 12(13.6%)
-- Imipenem for 14 days. 88 12(13.6%) 21(23.9%) 16(18.2%) 10(11.4%)
Nordback
et al.8 (2001) --Early prophylactic
imipenem 25 2(8%) - 2(8%) 2(8%)
--Delayed  imipenem 33 14(42%) - 14(42%) 5(15%)
Isenmann
et al.9 (2004) --Ciprofloxacin + 
Metronidazole for 14 days 58 12% - - 5%
-- Placebo 
56 9% - - 7%
Dellinger
et al.2 (2007) --Meropenem for
7-21 days 50 9(18%) 16(32%) 13(26%) 10(20%)
-- Placebo 50 6(12%) 24(48%) 10(20%) 9(18%)
Maravi-Poma
et al.25 (2003) --Imipenem for 14 days. 46 13 (28%) 5(11%) - 9(19.6%)
--Imipenem for more
than 14 days. 46 14(30.4%) 7(15%) - 8(17.4%)
Bassi et al.24
(1998) --Perfloxacin 14 days 30 10(34%) 13(44%) - 7(24%)
--Imipenem 14 days 30 3(10%) 6(20%) - 3(10%)
Comments
Randomized study of alcohol induced
Acute Necrotizing Pancreatitis (ANP) with
CT proven necrosis and CRP > 120.
All patients had acute alcoholic
pancreatitis with CT proven pancreatic
necrosis and 2 or more fluid collections.
Clinical course as assessed by APACHE
II score showed significant improvement
in patients under prophylactic treatment.
CT proven pancreatic necrosis.
Necrotizing pancreatitis proven by CT.
Patients randomly assigned within 72 hrs
of presentation.
CT proven necrosis. No control group
without prophylactic treatment. Both
groups received antibiotics.
CT proven necrosis. Early vs. on demand
imipenem treatment is compared.
Endpoint of study was necrosectomy due
to infection.
Placebo controlled double blind study. CT
proven necrosis. CRP > 150.
Protocol had to be opened in 48% of
placebo group for treatment of infectious
complications vs. 25% of antibiotics
group. 
Multicenter Randomized, Double-Blind,
Placebo-Controlled Study.  Primary
endpoint was development of pancreatic
or peri-pancreatic infection within 42 days
of randomization.
The second group received antibiotics for
as long as systemic complications of the
disease persisted.




Prophylactic antibiotics are beneficial
in reducing the incidence of severe
infection in ANP.
Antibiotic prophylaxis improved the
clinical course significantly.
Incidence of sepsis was
significantly less in imipenum
group. Prophylactic antibiotics are
recommended in ANP.
Meropenem is as effective as
imipenem in preventing septic
complications.
Early imipenem significantly
decreased the need for surgery
and major organ complications.
No difference in infectious
complications or mortality. No
benefit of prophylactic antibiotics in
ANP.
No statistically significant difference
between the two groups in outcome.
Does not early prophylactic antibiotic
use in patients with ANP.
Antibiotics for a longer duration do
not decrease septic complications
but in patients with systemic
complications till day 14 of treatment,
prolonged administration on
antibiotics tends to reduce mortality.
Pefloxacin is inferior to imipenem in
the prevention of infections in ANP.
related to the frequent use of prophylactic antibiotics in
patients with ANP. These infections are mostly secondarily
acquired during hospital admission. Candida infection of
pancreatic necrosis is associated with a significantly higher
mortality rate (p 0.0001) and fungal infection is an
independent predictor of mortality.27 A meta analysis by
Villatoro et al.11 found no significant difference between the
incidence of fungal infections between patients treated with
prophylactic antibiotics and those who were not. There is an
ongoing debate on the use of antifungal agents along with
prophylactic antibiotics. 
Evidence supporting the use of prophylactic antifungal
agents in acute necrotizing pancreatitis is lacking and more
research is needed in this area. Furthermore, the routine use of
antifungal agents can increase the incidence of resistant fungal
infections. Until more data is available, we do not recommend
the routine use of prophylactic antifungals along with
prophylactic antibiotics.  
Cost of management:
In Pakistan, a country where 32.6% of the people live
below the poverty line,14 and other low income and
developing countries, the cost of management of any disease
should always be taken into account. There is an enormous
difference in the cost of providing prophylactic antibiotic in
the setting of acute necrotizing pancreatitis vs. the cost of
managing serious complications later in an intensive care unit
(ICU) when prophylactic antibiotics are not given initially. In
a Canadian study the ICU costs per day were 6 to 7 times more
than non-ICU stay per day and there was an approximate
reduction of $ 1200 for one day in the general ward instead of
the ICU.28 In UK the cost per day for ICU stay has been
estimated to be $1357.29 Ten times more resources are
required for the treatment of acute necrotizing pancreatitis
after necrosectomy in ICU than the management of other
conditions in the ICU.30 The cost of an ICU bed per day in a
private tertiary care hospital in Pakistan is Rupees 6310 (US$
87) excluding the charges for medicines etc. compared to
Rupees 1570 (US$ 21) per day for a bed in a regular surgical
ward. The cost of 10 days of prophylactic imipenem is Rupees
27000 (US$365). Patients in ICU requiring a ventilator need
to pay an additional Rupees 35000 (US$ 455) per day
although this ventilator cost varies a lot depending on the
hospital as charges can be as low as Rupees 4000 (US$53) per
day; still a major burden on the majority of the patients. In
case surgical intervention is needed, the cost of a scheduled
laparotomy is approximately Rupees 150,000 (US$ 1950) in a
tertiary care setting and approximately Rupees 50000 (US$
660) at a private hospital. Keeping in view the serious
infective complications of acute necrotizing pancreatitis, the
enormous cost of surgery and intensive care needed for
managing these complications and the universal non-
availability of tertiary care in a developing country,
prophylactic use of imipenem in acute necrotizing pancreatitis
will be favourable for the patient.
Indications of prophylactic antibiotic in ANP:
The severity of ANP is dependent on the degree of
pancreatic necrosis. The degree of pancreatic necrosis is best
established by contrast enhanced CT which is fast and
reliable.31 Pancreatic necrosis develops 24 to 48 hours of onset
of symptoms.32 CT scan done within 12 hours of onset of
symptoms may fail to reveal necrosis. The optimum time for
a CT scan is approximately 48 hours after the onset of
symptoms. There is a low risk of infected necrosis if the
necrosis is less than 30%.33 Thus prophylactic antibiotics can
be avoided in such patients if there is no organ failure or local
complication. The UK guidelines for the management of acute
pancreatitis33 suggest that antibiotics should only be
considered for patients with more than 30% necrosis. 
In severe acute pancreatitis, fluid collections are
common but most resolve spontaneously. Patients with peri-
pancreatic fluid collections without evidence of necrosis still
have a 22% incidence of local complications.34 In such cases,
as most of these collections resolve spontaneously, antibiotics
should not be given if there is no evidence of sepsis or organ
failure. If needed, material should be obtained for culture and
sensitivity by FNA and should guide antibiotic therapy. 
If the facility of CT scan is not available or if there is a
delay, C- reactive protein levels can be used to predict the
development of pancreatic necrosis. According to the Sartorini
consensus,35 CRP levels start to rise above 150 mg/l within 48
hours and differentiate between mild and severe disease. Hence,
prophylactic antibiotics can be useful if the CRP is above
150mg/l (the value agreed upon at the Sartorini consensus),
within 48 hours of onset of symptoms until the patient can be
transferred to a higher level facility for a CT scan. 
In summary, prophylactic antibiotics in ANP have
been recommended in patients with CT evidence of more than
30% pancreatic necrosis or in patients with significant
elevation of C-reactive protein.
Conclusion
The current data available on the use of prophylactic
antibiotics in acute necrotizing pancreatitis is not in agreement
on its effect on patient outcome. Conclusions of various meta-
analyses are different. Until more randomized trials are
available that clearly show no change in outcome with the use
of antibiotics, the use of imipenem as a prophylactic antibiotic
for 10 to 14 days is recommended in ANP with more than 30%
necrosis, especially in settings of developing countries where
tertiary care is not readily available, majority of patients are
unable to bear the financial burden of management of
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complications after ANP, and where health care insurance is
the exception rather than the rule. Thus in settings of
developing countries the use of imipenem as prophylaxis in
ANP can be cost effective and prevent severe and potentially
fatal infective complications. Prophylactic antibiotics for
patients with fluid collections are not recommended if there
are no signs of sepsis or organ failure. Routine use of
prophylactic antifungals is not recommended in acute
necrotizing pancreatitis but the decision should be
individualized for each patient.
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